Skip to content
Screener

Climb Bio, Inc. CLYM Q3 2025 earnings

Reported November 6, 2025 · Before market open

EPS-$0.19Miss by $0.03
EPS estimate-$0.16

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.19

Financials

Q3 2025

Income statement

See full
Operating income-$14.9M-26.9%
Net income-$12.9M-44.9%
EPS (diluted)-$0.19-46.2%

Balance sheet

See full
Cash & equivalents$25.8M-82.3%
Total debt$580.0K+900%
Total equity$177.0M-19.1%
Total assets$182.3M-18.0%

Cash flow

See full
Operating cash flow-$12.1M-60.7%
CapEx$109.0K—
Free cash flow-$12.2M-62.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$136.21M—
Enterprise value$110.98M—

Returns & leverage

See full
Return on equity-25.6%-7.2pp
Debt / equity0×0.0×
Current ratio18.4×-39.4×

FAQ

When did Climb Bio, Inc. report Q3 2025 earnings?
Climb Bio, Inc. (CLYM) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Climb Bio, Inc.'s Q3 2025 revenue and EPS?
Climb Bio, Inc. reported eps of $-0.19 for Q3 2025.
Did Climb Bio, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.16 by $0.03.
How did Climb Bio, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 46.2% from $-0.13.
Where can I find Climb Bio, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268075) and the 10-Q periodic report (0001193125-25-268086) directly on SEC EDGAR. The filing index links above go to sec.gov.